Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Renoprotection with and without blood pressure reduction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Low C4 gene copy numbers are associated with superior graft survival in patients transplanted with a deceased donor kidney

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Need for better diabetes treatment for improved renal outcome

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Progression of diabetic nephropathy in normotensive type 1 diabetic patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Describing the fecal metabolome in cryogenically collected samples from healthy participants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Carotid-femoral pulse wave velocity is a risk marker for complications in persons with type 1 diabetes

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskning

Vis graf over relationer

BACKGROUND: AT1-receptor blockade dose dependently lowers blood pressure (BP) and albuminuria. Reduction of BP and albuminuria are independent treatment targets for renoprotection, but whether this requires similar dose titration is unknown.

METHODS: We tested this in two studies designed to find the optimal antialbuminuric dose of losartan in type 1 diabetic (DM, N= 50) and nondiabetic renal patients (ND, N= 12). After baseline, treatment followed with losartan 50, 100, and 150 mg/day, each dose for eight (DM) or six weeks (ND). At the end of each period, albuminuria (24-hour samples) and mean arterial pressure (MAP) were measured. Patients were divided into "good" and "poor" BP responders (BP+, BP-) according to BP response above or below group median.

RESULTS: Baseline MAP in the BP- groups was 102 (97, 104) mm Hg in DM (median, 95% CI) and 91 (80, 108) mm Hg in ND. The top of the dose response for BP (obtained at losartan 100 mg) in the BP- groups was -2 (-4, 3) mm Hg in DM and -1 (-6, 2) mm Hg in ND, versus -15 (-18, -12) mm Hg and -16 (-26, -18) mm Hg in BP+ groups (both P < 0.05). Albuminuria was reduced dose dependently both in BP- and BP+: with 100 mg, the reduction in albuminuria in DM BP- was -32% (-49, 13) versus -45% (-60, -38) in DM BP+ and -45% (-70,-7) versus -25% (-58, -6) in ND BP- and BP+ (all P > 0.05). Moreover, in patients in whom BP fell below the recommended treatment target of 130/80 mm Hg (13 in DM and 10 in ND), albuminuria was progressively reduced, with further increasing the dose of losartan in most patients.

CONCLUSION: Absence of BP response to losartan does not preclude a reduction in albuminuria, and optimal reduction of albuminuria may require titration beyond the predefined BP target.

OriginalsprogEngelsk
BogserieKidney International, Supplement
Udgave nummer94
Sider (fra-til)S54-9
ISSN0098-6577
DOI
StatusUdgivet - apr. 2005

ID: 52009551